SLC
VRTX icon

Second Line Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Second Line Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$508K Buy
1,189
+45
+4% +$21K 0.1% 86
2025
Q4 		$519K Buy
1,144
+29
+3% +$12.5K 0.11% 74
2025
Q3 		$437K Buy
+1,115
New +$466K 0.09% 85

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Second Line Capital's VRTX Position: Q1 2026 in Review

Second Line Capital increased its Vertex Pharmaceuticals (VRTX) stake by 3.9% in Q1 2026, buying an estimated $21K and bringing the position to 1,189 shares worth $508K. The position accounts for 0.1% of the portfolio, ranked #86.

Second Line Capital first reported a position in VRTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $519K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Second Line Capital held 1,189 shares of Vertex Pharmaceuticals worth $508K as of Q1 2026.
  • Second Line Capital bought 45 Vertex Pharmaceuticals shares in Q1 2026, an estimated $21K.
  • Vertex Pharmaceuticals made up 0.1% of Second Line Capital's portfolio in Q1 2026, its #86 holding.
  • Second Line Capital first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Second Line Capital's Vertex Pharmaceuticals position peaked at $519K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Second Line Capital's 13F filing for Q1 2026, filed 15 May 2026.